Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis [1]

Inflammatory Bowel Diseases

Volumn 13, Issue 8, 2007, Pages 1055-1056

  Fukunaga, Ken ^a   Ohda, Yoshio ^a   Inoue, Taku ^b   Kono, Tomoaki ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; METHYLPREDNISOLONE;

ADOLESCENT; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LABORATORY TEST; LETTER; MALE; PRIORITY JOURNAL; SKIN DEFECT; TOXIC EPIDERMAL NECROLYSIS; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; EPIDERMAL NECROLYSIS, TOXIC; HUMANS; MALE; MESALAMINE;

EID: 34548172712     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20125     Document Type: Letter

References (7)

1. Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds.). Inflammatory bowel disease. London: Mosby; 1998:121-140.
2. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96:1116-1122.
3. Rouyeau J-C, Sterm RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
4. Caron GA, Sarkany I. Lymphoblast transformation in sulphonamide sensitivity. Br J Dermatol. 1965;77:556-560.
5. Iemoli E, Piconi S, Ardizzone S, Porro GB, Raimond F. Erythroderma and toxic epidermal necrosis caused by 5-aminosalacylic acid. Inflamm Bowel Dis. 2006;12:1007-1008.
6. Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci. 1983;28:833-843.
7. Clemen D, Markham A. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs. 2000;59:929-956.